Mediphage Bioceuticals is a genetic medicine company focused on developing safe, effective, and accessible gene delivery platforms to unlock the therapeutic power of personalized, redoseable, genetic medicine.
Mediphage Bioceuticals was formed as a spin off company from the University of Waterloo in Ontario, Canada.
Mediphage Bioceuticals closes its seed round to develop proof of concept and perform early stage efficacy studies.
Proof of Concept.
Mediphage Bioceuticals successfully develops its DNA Ministring production and targeting technology. Mediphage also completes early stage proof of concept efficacy studies.
JLABS @ MaRS Toronto.
Mediphage Bioceuticals moves to JLABS at the MaRS Discovery District. Mediphage enters late stage safety and efficacy studies and executes feasibilty studies with key biopharma partners.
Mediphage Bioceuticals moves to San Francisco for the Illumina Accelerator program, carrying out key genomics projects and initiating Mediphage's next round of funding.
Mediphage Bioceuticals implements large-scale, high speed msDNA manufacturing to support growing biopharma partnerships and internal therapeutic development efforts.
Our flagship technology, ministring DNA (msDNA), is a safe, effective and highly accessible nonviral gene delivery vector for the redoseable delivery of genes into cells for gene therapy, cell engineering and gene editing. Unlike conventional viral and nonviral gene delivery systems, msDNA has a linear covalently closed “string” topology, making it the safest tool for gene delivery without compromising effectiveness, and can be produced at a fraction of the cost of competing solutions.
Here’s how we compare:
Highly scalable and efficient production: Mediphage Bioceuticals’ patented E.coli “in vivo” production system allows for the rapid production of large scale quantities of msDNA, while being highly cost-effective.
Safer composition and design: msDNA is the only vector capable of protecting individuals from harmful mutations by selectively inducing cell death upon undesired chromosomal integration.
Redoseable and personalized gene therapy: msDNA contains no immunostimulatory components, which enhances safety and allows for redoseable administration.
Large vector capacity: msDNA has a substantially large vector capacity, and can be used to treat monogenic disorders for which therapeutic genes exceed traditional vector capacity.
With the highest safety profile across viral and nonviral transgene delivery vectors, msDNA enhances the transition of current genetic engineering technology into true personalized genetic medicine.
Current Applications of msDNA
Ministring DNA is an efficient, customizable and redosable vector for ex vivo and in vivo cell or gene therapies, and lymphocyte (B-cell and T-cell), stem cell and gene editing therapeutics. Our msDNA technology is currently being evaluated by therapeutic development partners using gene therapy, chimeric antigen receptor T-cells, DNA vaccines, induced pluripotent stem cells, CRISPR and B-cell immunotherapy approaches, as well as recombinant adeno-associated viral production, across a variety of applications.
CEO, MSc, BA
18 years experience leading life science companies
formerly CEO of Previvo Genetics, COO of Neomorphic Software (bioinformatics), and VP and CIO of Affymetrix, Inc. (microarray technology and genomics analysis)
Dr. Roderick Slavcev,
Founder & CSO, Executive Director,
HBSc, PhD, MBA, MRSB, C.Biol
Associate Professor, Pharmaceutical Sciences
Professor, Business & Entrepreneurship School of Pharmacy, University of Waterloo
Chartered Biologist, Royal Society of Biology
Chief Operating Officer
MA - International Relations
BMath - Computer Science (Bioinformatics)
Director of R&D, PhD, MSc
B.W. Pearson Research Medal (2014)
University of Waterloo School of Pharmacy Award of Excellence (2013)